IGF1 and obesity disorder: Because the production of both IGF‐1 and IGFBP‐3 occurs primarily in the liver (Allard & Duan, 2018; Blum et al., 1993), our findings suggest the presence of shared hepatic mechanisms that inhibit the secretion of both IGF‐1 and IGFBP‐3 in response to exercise in individuals with obesity.